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FOREWORD
Even before the Covid-19 emergency, global rates of depression were 
staggeringly high. It would be surprising if they did not rise further 
still in response to the measures taken to contain the virus. Since the 
advent of modern antidepressants in the late 1980s, the use of these 
medications has become so widespread that they are almost ubiqui-
tous in the treatment of depression. This is despite their often severe 
side effects, and the fact that they are so regularly ineffective; usu-
ally working to minimise the symptoms of depression rather than 
alleviate the disease itself. 
Psychedelic medicines such as psilocybin act in an entirely differ-
ent way, being administered once or twice by a clinician in a clini-
cal setting and getting to the root of the suffering. Patient access to 
this novel psychiatric intervention remains totally illegal in the UK, 
outside of the small sample sizes of the very few and hugely costly 
on-going clinical trials. The reports of those lucky enough to have 
received this treatment legally read as unequivocal endorsements, 
yet the possibility of scaling up the research necessary to roll out 
these treatments on the widespread scale so desperately needed 
remains at almost impossible reach.  
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The Misuse of Drugs Regulations 2001 deems psilocybin, along with 
many other potentially revolutionary medicines, harmful and lack-
ing medical potential. This results in psilocybin, along with many 
other substances vested with therapeutic potentials, being erro-
neously perceived as such. Coupled with the Misuse of Drugs Act 
1971, this absurd cross-hatching of prohibitive scheduling has led 
to a scientific blackout lasting nigh on fifty years, precluding new 
treatments and, with them, the prospect of a better life for millions 
of people. 
A move of psilocybin from Schedule 1 to Schedule 2 of the 2001 
Regulations, with restrictions strictly limiting its availability to reg-
istered clinical trials and experimental research studies, not only has 
the potential to deliver new treatments for patients, but also establish 
the UK as the world leader in psychedelic research, growing the UK 
drug development industry and advancing public health. Such a pol-
icy change also has the potential to significantly diminish the cost of 
research, reducing in turn the cost of the final product, which will no 
doubt translate into significant savings for the NHS later on. 
Thousands of men and women from the armed forces, policing and 
front line medical staff are suffering today from psychological inju-
ries incurred through service to their country. They are unable to 
find effective treatment in the UK. For these individuals to gain legal 
access to psilocybin, a substance deemed safe in humans with the 
potential to provide them with lifesaving psychotherapeutic relief, 
they are forced to break the law or travel abroad. This report makes 
the case for removing existing unnecessary blocks to research and 
drug development so we can unlock the evidence and deliver for 
them. 
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In the Netherlands, retreat centres with professional sitters already 
facilitate experiences with psychedelics for those seeking healing in 
safe and supportive environments. I am a trustee of Heroic Hearts 
UK, a charity run by and for UK veterans and ex-service staff, that 
provides preparation, access to and integration of the potentially 
psychotherapeutic psilocybin experience through such retreats. As 
a veteran myself, I am acutely aware of the urgent need for effec-
tive treatment options for this population, and for veterans to be able 
to access them closer to home at a fraction of the current costs. The 
wretched position those who have served with such courage are in, 
unable to alleviate their symptoms with current treatment and unable 
to benefit from new treatments due to a de facto block on the science, 
is unacceptable. 
Psilocybin and other Schedule 1 substances must be put through the 
rigours of research and large scale randomised controlled trials for 
a fair demonstration of their medicinal potential, and the law must 
change to make that possible. 
As we emerge from the social, economic and mental health effects 
of the Covid-19 pandemic, we have the opportunity to stimulate the 
UK economy, position ourselves as a world leader in the field of psy-
chopharmacology and drug development, and facilitate the provision 
of treatment to those who need it most. We call for nothing more than 
this opportunity be taken. Doing nothing is senseless, morally wrong 
and frankly incomprehensible.
This report pays consideration to the ethical, medical, economic and 
criminal implications of psilocybin’s current status as a Schedule 
1 substance with the aim to move the UK into an evidence based, 
intelligent and reasoned position concerning this potentially revo-
lutionary psychiatric intervention. An overdue move and one which 
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would enable the thousands, if not hundreds of thousands, currently 
in unnecessarily prolonged distress to access the treatment they both 
deserve and require. 
Chairman, CDPRG
Crispin Blunt MP
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EXECUTIVE 
SUMMARY
• Psilocybin is a compound found in over 100 species of fungi. In 
humans, it induces temporary changes in mood, perception and 
cognition via activation of serotonin receptors in the brain. It is asso-
ciated with a low potential for harm relative to other classes of psy-
choactive drugs: it has very low toxicity, its use is not associated with 
the development of physical dependence, nor with acquisitive or other 
crime, and deaths attributed to its abuse are extraordinarily rare. It is 
listed in Class A of the Misuse of Drugs Act 1971 and in Schedule 1 of 
the Misuse of Drugs Regulations 2001. There is overwhelming scien-
tific consensus that the current legal status of psilocybin is not evi-
dence-based, but rather grounded in overstated historical assumptions 
of harm.
• Depression is among the most significant social, economic and medi-
cal challenges in the UK. It is the greatest contributing factor to sui-
cide, a leading cause of disability, and it costs the economy £10 billion 
annually. Existing therapies are not adequate for approximately 30% of 
patients; 1.2 million British residents are estimated to be living with 
treatment-resistant depression. Since very few advances have been 
made in the treatment of depression in several decades, there is an 
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urgent need to support research into novel therapies for treat-
ment-resistant cases.
• Psilocybin is being investigated as a novel therapy for treat-
ment-resistant depression and other difficult-to-manage men-
tal health conditions, including obsessive-compulsive disorder, 
substance misuse disorders, and end-of-life anxiety. In 2018, the 
British life sciences company Compass Pathways received FDA 
‘Breakthrough Therapy’ designation for psilocybin. Evidence 
from completed early phase trials indicates that psilocybin can be 
used safely and feasibly, is well tolerated by patients, and that 
it is likely to have lasting therapeutic benefits. However, robust 
evidence on efficacy can only be generated by large-scale phase 3 
controlled clinical trials. Compass intend to start phase 3 at UK 
sites in the near future. These trials will be greatly enabled by 
rescheduling.
• Although trials are successfully being undertaken, Schedule 
1 regulations are a major barrier, increasing the costs, dif-
ficulties and duration of research. Schedule 1 research typi-
cally requires multiple Home Office licenses per study, incur-
ring significant administrative costs and delays. Compliance 
with Schedule 1 safe custody and security regulations add 
further substantial burdens of cost and time. In practice, these 
requirements necessitate contracting specialised pharmacies to 
do what could otherwise be done by hospital pharmacies at trial 
sites. Additionally, stigma associated with Schedule 1 negatively 
impacts funding, ethical approval, and collaboration. These 
barriers, which are well known among the research community 
and have been recognised in Parliamentary reports for at least 
twenty years, prevent many studies from taking place and sub-
stantially complicate those that do.
• A scheduling review is undertaken as part of the normal pro-
cess when a medicinal product achieves market authorisation, 
but significant savings could be made by moving psilocybin 
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to Schedule 2 prior to the commencement of phase 3 trials. This 
would have wide-ranging benefits: to legitimate commercial drug 
development through reduced barriers to research; to the tax-
payer through decreased expenditure of Government research 
grants; and to the NHS and British patients through lower end-
costs of treatment and earlier completion of trials. Greater 
regulatory support for psilocybin research will ensure the UK’s 
reputation as a global centre of excellence in this area, attract 
commercial investment and international expertise, and pre-
vent a ‘brain-drain’ of British research and innovation to other 
jurisdictions. Immediate action will yield the greatest benefits 
to the UK.
• In November 2018, a precedent was set for moving controlled 
drugs (cannabis-based products for medicinal use (CBPM)) 
from Schedule 1 to Schedule 2 prior to market authorisation as 
a medicine. At the time, the Home Office wrote: “The resched-
uling may lead to increased UK research [...] as these products can 
be tested more easily.” “This may lead to economic benefits for UK 
businesses and health benefits to patients if this research leads to new 
and improved [medicinal products].” “In principle, research is ongo-
ing and could lead to more effective treatment, lower costs, better 
understanding and management of risks, and improved health 
and wellbeing, over the medium term.” The current Chief Medical 
Adviser to the UK Government, Prof Chris Whitty, later stated 
that moving CBPM to Schedule 2 was “the single most important 
thing that could be done by Government” to support the develop-
ment of an evidence base.
• Likewise, rescheduling would be the most significant and 
immediate way that Government could support ongoing 
research with psilocybin. Psilocybin could be rescheduled 
with statutory limits restricting access to ethically-approved 
research studies only – unless a product has market authorisa-
tion – thus preventing wider prescribing on an unlicensed basis. 
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This would be unprecedented in UK law, but would serve to sup-
port scientific development without risking inappropriate 
prescribing. 
• The major source of diverted medicinal drugs is by prescription 
prior to diversion. Moving psilocybin to Schedule 2 for research 
purposes is unlikely to increase the risk of diversion because 
the drug is administered to participants under clinical supervi-
sion, rather than being prescribed for use in the community. This 
is in line with ACMD advice that “the risk of diversion and mis-
use in a research setting is likely to be minimal.”
• The proposed research-only model of rescheduling would sup-
port legitimate scientific and commercial development while 
maintaining stricter controls on psilocybin than on other con-
trolled drugs associated with greater potential for harm, includ-
ing diamorphine (heroin), methamphetamine, and cocaine. It 
would not affect existing legal controls on criminal use or sup-
ply. This model may also serve as a basis for future scheduling 
decisions; there are other Schedule 1 drugs under investigation 
as treatments for mental health conditions for which there are 
similar clinical arguments to support rescheduling, albeit with 
less immediate urgency. 
• The ongoing ACMD review on barriers to research with 
Schedule 1 drugs is vital. We also welcome the current work to 
establish a Standard Operating Procedure (SOP) for scheduling 
decisions. However, the primary emphasis of the review on bar-
riers to research is on synthetic cannabinoids and it is currently 
unclear whether the SOP will be used to review historical sched-
uling decisions. Since neither report is expected to be published 
until 2021, nor to directly provide recommendations on psilocy-
bin, there is no known work currently commissioned by the 
Home Office that addresses the urgent issues identified in 
this report.
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• We recommend that the Home Office commission a high-pri-
ority ACMD review into the access-restricted rescheduling of 
psilocybin under the Misuse of Drugs Regulations 2001.
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“There were times in the whole experience where I felt like I was being 
purged of self doubt, guilt and was being shown ways of handling all 
that was bringing me down. It was like having the best therapist in 
the world inside your mind, but all the answers were within. I cried 
at times, I laughed and afterwards felt totally moved by it all… My 
doctor was amazed also. I didn’t want any more anti-depressants, nor 
have I taken any in 5 years now … 
It is beyond ridiculous to think that this drug has no medicinal benefit, 
or that it causes harm. It is the polar opposite of that. It saddens 
me that others, who have also battled with or are still battling with 
depression can’t benefit from this… It changed my life totally, and it 
has done for others. It needs to be made available soon.” 
-  Clinical Trial Participant
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INTRODUCTION 
Psilocybin is a naturally occurring molecule found in almost 150 
species of mushrooms in the genus Psilocybe.1 It is psychoactive 
in humans and classified as a ‘psychedelic’ alongside lysergic acid 
diethylamide (LSD), 3,4,5-trimethoxyphenethylamine (mescaline) 
and N,N-dimethyltryptamine (DMT). Psychedelic drugs induce 
temporary alterations in mood, perception, and cognition (‘psyche-
delic experiences’) through activation of specific serotonin receptors 
in the cortex of the brain.2 3 The traditional use of psilocybin-contain-
ing fungi, mescaline-containing cacti, and DMT-containing plants, 
by geographically disparate cultures, is thought to date back hun-
dreds, if not thousands, of years.4 5 
Psilocybin is the phosphate ester of psilocin and is thus listed, 
though not specifically named, under Class A of the Misuse of 
Drugs Act 1971, under Schedule 1 of the Misuse of Drugs Regulation 
2001, and in Part 1 of the Misuse of Drugs Designation Order 2015. 
Accordingly, neither psilocybin or fungi containing psilocybin can 
lawfully be produced, prescribed or possessed, except under a license 
or other authority issued by the Home Office, and offences relating 
to the unauthorised use and supply of psilocybin may incur the most 
severe of the criminal penalties described in the 1971 Act.6 7
Psilocybin is being investigated as a treatment for a range of mental 
health and substance misuse disorders, including depression, nico-
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tine addiction, obsessive-compulsive disorder, and existential dis-
tress and anxiety in life-threatening cancer. Phase 1 (first-in-human) 
and phase 2 (first-in-patient) clinical trials in the UK, Europe and 
the US have provided preliminary evidence for the safety, feasibil-
ity and tolerability of psilocybin in research conditions. Early phase 
clinical trials are not designed to generate robust evidence of effi-
cacy, but all published trials to date have reported positive findings 
on outcome measures of efficacy, justifying the need for continued 
research (Table 1). A systematic review that included historical clin-
ical trials in unipolar mood disorders indicated that 80% of patients 
who received psilocybin showed clinical improvement.8 Phase 2 trials 
are presently underway in the UK to investigate psilocybin as therapy 
for treatment resistant depression, a condition with an estimated 1.2 
million British sufferers for which there have been no major advances 
in decades.9 
There is also a recent upsurge in preclinical studies on psilocybin and 
related molecules for early stage drug discovery in animals and in in 
vitro systems. This work is essential to enable our understanding of 
how these substances produce beneficial and long-lasting effects in 
the brain. This work is mostly undertaken in higher education insti-
tutions (HEI) and will increasingly form part of that economy.   
However, strict regulatory controls in the UK continue to slow the 
pace of the science. Schedule 1 regulations do not preclude legiti-
mate scientific studies, but they do increase the cost, difficulty and 
duration of research in three main ways. Firstly, a single study will 
typically require multiple separate Schedule 1 licenses. It may take 
months or years for all license applications to be granted and the 
cumulative annual cost can have a substantial impact, particularly on 
smaller studies. Secondly, all study sites must meet extremely strict 
security standards, which, in practice, requires contracting external 
pharmacies to do what could otherwise be done by hospital pharma-
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cies, at the cost of tens of thousands of pounds each year. The delays 
and costs associated with these regulations are particularly signifi-
cant for large-scale, multi-site trials, and the increased expense of 
bringing a Schedule 1 drug to market may ultimately increase the 
end-cost of the treatment. Thirdly, the stigma of Schedule 1 nega-
tively impacts funding, staffing, buy-in from collaborators, and ethi-
cal approval. 
The burdens of Schedule 1 are well known in the research and com-
mercial pharmaceutical communities; they prevent many stud-
ies from taking place – and substantially complicate those that do.10 
Large-scale phase 3 trials are exceptionally difficult to undertake 
under Schedule 1 controls, yet they must be done to determine the 
efficacy of psilocybin for market authorisation as a medicine, which 
will further develop its commercial potential. Acting swiftly to 
review the controls on psilocybin is the single greatest contribution 
that the Government could make to support research in this area. 
The challenges posed to research with psilocybin are not unique. 
Clinical trials with other Schedule 1 drugs, such as methylenediox-
ymethamphetamine (MDMA), are subject to the same financial 
and practical obstacles. Until November 2018, when cannabis-based 
products for medicinal use (CBPM) were moved to Schedule 2 of the 
2001 Regulations, there was no precedent for the rescheduling of a 
Schedule 1 drug prior to market authorisation. The rescheduling of 
CBPM was intended to permit their prescription as unlicensed medi-
cines to treat patients with a special clinical need, but it was also rec-
ognised that it would be significantly easier for scientists to research 
CBPM under Schedule 2 controls. 
The decision to reschedule CBPM came in response to several high-
profile cases of children with treatment-resistant epilepsy in the 
British media.11 Every year in the UK, almost three times more peo-
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ple with depression or another mood disorder die from suicide than 
die from complications of epilepsy, which suggests a stronger clini-
cal argument to support the rescheduling of psilocybin.12 13 14 In the 
absence of Government action to review psilocybin, similar media 
campaigns are likely to increase the public and political pressure to 
do so.
This paper will outline the scale of the UK mental health crisis, 
the urgent need to support promising new therapies, and the ongo-
ing clinical research into psilocybin as a potential treatment for 
depression and other mental health conditions. Qualitative testimo-
nies from clinical scientists, industry, and scientific advisers to the 
Government are provided to illustrate the difficulties of research 
with Schedule 1 drugs. A quantitative cost-benefit analysis of 
rescheduling is to be published by the CDPRG in a subsequent report. 
Finally, this paper suggests routes to ease restrictions on psilocybin 
research while maintaining existing legal controls on non-medical or 
scientific use and minimising potential risks of diversion and inap-
propriate prescribing.




IN THE UK 
THE BURDEN OF MENTAL ILLNESS
Depression and other mental illness remain among the most signifi-
cant social, economic, and medical challenges of the modern world. 
Mental illnesses, including substance misuse, account for over 22% 
of disability in the UK – the largest of any medical illness category 
– with the leading cause being depression and anxiety.15 Cancer and 
cardiovascular disease, by comparison, account for about 16% each.16 
In England, 1 in 6 people experience a common mental health prob-
lem – such as anxiety and depression – in any given week.17 Fifty per-
cent of mental illnesses are established by age 14, with this figure ris-
ing to 75% by age 24.18 The personal and social burden to society is 
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thus cumulative throughout one’s lifespan. Children and adolescents 
with mental illness have poorer educational outcomes and job pros-
pects, while adults are less likely to be productive and more likely to 
receive government benefits. Public Health England has found that 
nearly 51% of those receiving the Employment Support Allowance list 
a mental and behavioural health problem as their primary condition.19 
Poor mental health has also been associated with increased health-
damaging behaviour, including smoking, drug misuse and alcohol-
ism, and less participation in community life.
Depression is the largest contributing factor to suicide, which 
remains the leading cause of death in men under 50 and women 
under 35, with men three times more likely to die from suicide than 
women.20 Those with ongoing depression are twenty times more 
likely to commit suicide than the general population, and those with 
treatment resistant forms of the illness are, logically, at even higher 
risk.21 Approximately 30% of people with treatment resistant depres-
sion attempt suicide at least once – ten times the incidence found in 
people with non-resistant depression.22 Suicide and suicidality have 
a particularly devastating impact on families and communities. In 
2018, there were 6,507 deaths by suicide in the UK, at a rate of just 
over 11 deaths per 100,000 people.23 A reduction of approximately 
10% on this metric would equate to preventing all the deaths caused 
by murder in England and Wales.24 The link between suicide and 
mental illness is clear, with numerous studies concluding that a high 
number of people who survive a suicide attempt have suffered from 
mental illness.25 
In 2010, the Centre for Mental Health estimated the combined cost 
of lost productivity, spending on health services and reduced qual-
ity of life as a result of mental health problems at £105.2 billion per 
annum, of which more than £53 billion was attributed to reduced 
quality of life alone.26 27 In 2013, Britain’s Chief Medical Officer esti-
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mated the annual cost of mental health problems at £70-100 billion.28 
1 in every 10 pounds of the NHS budget is spent on mental illness.29 
A 2018 OECD report, which omitted the burden of reduced quality 
of life, concluded that mental illness costs the UK economy £94 bil-
lion per annum, or 4.1% of GDP, in line with the EU average of 4%. 
The indirect costs of mental illness also have a significant impact on 
individuals, reducing disposable income, financial security and work-
force participation.30 The toll is felt by business, too: a recent report 
by the Centre for Mental Health concluded that mental health prob-
lems cost UK businesses £34.9 billion in 2016/17, growing 34% since 
from 2006 (£25.9 billion).31 
Depressive disorders are a major contributor to these costs. In 2007, 
direct treatment costs and costs of lost employment associated with 
depression in the UK were estimated at a total of £7.5 billion per year, 
rising to more than £10 billion by 2020.32 These figures are likely to 
underestimate the true economic burden, since they do not include 
indirect costs due to morbidity and mortality, which have been esti-
mated to contribute almost two-thirds of total healthcare costs.33 A 
disproportionate humanistic and economic burden is associated with 
treatment resistant depression, which is associated with significantly 
lower quality of life, greater impairment to activity and work pro-
ductivity, and increased healthcare resource utilization compared to 
non-resistant forms of the disease.34 35 36
EXISTING TREATMENTS FOR DEPRESSION
Selective serotonin reuptake inhibitor (SSRI) drugs and other struc-
turally similar antidepressants offer a modest benefit for many 
patients; a rigorous 6-year evaluation by Oxford researchers found 
that about 60% of patients taking antidepressants responded within 
two months, and those who responded had a 50% reduction in their 
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symptoms.37 However, approximately 10 – 35% of people with depres-
sion do not respond to at least two antidepressants.38 39 The National 
Institute for Health and Care Excellence (NICE) recommend that 
all treatment resistant patients should be referred to a specialist, but 
these targets are commonly missed.40
The prevalence of treatment resistant depression is difficult to esti-
mate, partly due to inconsistencies in its definition and to differing 
findings of symptom response and remission after treatment with 
common antidepressants. A 2007 review of treatment-resistant 
depression in the United States estimated the 12-month prevalence 
of major depressive disorder (MDD) at 6.6%, of whom an estimated 
35% do not respond to two courses of treatment.41 Extrapolating these 
findings would result in an estimate of approximately 1.2 million 
adults in the UK with treatment-resistant depression. Estimates of 
prevalence based on the number of people who have been prescribed 
antidepressants are rather higher, at up to 2.7 million, but may be less 
accurate.42 A Public Health England report found that approximately 
7.3 million people in the UK had been prescribed an antidepressant 
between 2017-18.43 
Progress in the treatment of depression has been slow. Prior to the 
approval of esketamine by the European Commission in late 2019, 
the last major advancement in the treatment of depression came 
over 30 years ago with the licensing of SSRIs.44 A 2017 report by the 
UK Department of Health noted that “the pharmaceutical sector 
has undergone significant change with many larger companies scal-
ing back mental health research portfolios.” Recommendations were 
made for encouraging industry engagement in mental health research 
and for the streamlining of procedures for the regulation, governance 
and ethical oversight of research to expedite studies.45
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2. PSILOCYBIN 




Psilocybin was first isolated and synthesized in 1958 and was subse-
quently marketed under the trade name Indocybin by the Swiss phar-
maceutical company, Sandoz.46 Throughout the late 1950s and 1960s, 
psilocybin and other psychedelic drugs were investigated as potential 
treatments in hundreds of clinical studies internationally, with tens 
of thousands of patients treated.47 48 Researchers noted that psilocy-
bin showed negligible toxicity in animals and humans, and induced 
suggestibility, introspection and awe in the latter. While the evi-
dence was mixed, these effects proved transformative in the context 
of psychotherapy for some patients who had otherwise been unwell 
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and unproductive for years.49 50 A 2016 systematic review of historical 
studies in unipolar mood disorders found that 80% showed clinically-
judged improvement after treatment with psychedelic drugs.51
Research was primarily funded by pharmaceutical companies, the 
US National Institute of Mental Health (NIMH), and military and 
intelligence agencies – which retained interests in the application of 
psychedelics in espionage and warfare.52 53 54 While studies often suf-
fered from methodological limitations, they commonly identified 
a therapeutic potential of psychedelics – when delivered within safe 
and supportive settings – for sufferers of depression, anxiety, addic-
tion, and obsessive disorders. They were ineffective in military and 
intelligence settings and unhelpful for those with pre-existing psy-
chotic disorders.55 56 57 
Regulations on clinical research were tightened in the early 1960s in 
response to the Thalidomide tragedy. In 1962, the Kefauver Harris 
Amendments to the US Federal Food, Drug, and Cosmetic Act 
strengthened regulations in drug research, enshrining a requirement 
for evidence of efficacy and, particularly, safety, to be established 
through controlled clinical trials. 58 59 A consequent increase in the 
cost of clinical research, coupled with growing controversy and polit-
ical disapproval regarding the non-medical use of psychedelic drugs, 
as well as the impending loss of patent for LSD, led Sandoz to cease 
production of psilocybin in 1965. 60 61 62 63 64
The Misuse of Drugs Act was passed in 1971, swiftly followed by 
the Misuse of Drugs Regulations 1973, prohibiting the use of psilo-
cybin and other psychedelic drugs unless specifically licensed by the 
UK Government.65 66 67  The medical use of psychedelics, which had 
been well established in specialist hospitals, ceased as doctors were 
prohibited from prescribing outside of authorised clinical trials. The 
legal restrictions on the use of psilocybin did not reflect an absence of 
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therapeutic value, nor scientific evidence of harm, but rather a per-
ception of harm by political leaders at the time.68 In the face of socio-
political opprobrium, institutional and grant support for psyche-
delic research dried up.69 This previously vibrant and promising field 
entered a period of hibernation that lasted 25 years. 
CONTEMPORARY PSILOCYBIN RESEARCH 
Contemporary research with psilocybin and, to a lesser extent, other 
psychedelics, resumed with the publication of several Phase 1 clini-
cal trials in Germany, the USA and Switzerland in the 1990s.70 71 72 
These, and successive studies, have established basic pre-clinical and 
in-human safety data.73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 
Phase 2 trials, necessarily small in scale, have also been completed. 
A number of groups have reported the safety and efficacy of psilocy-
bin in patients with treatment resistant forms of depression, obses-
sive compulsive disorder (OCD), end-of-life psychological distress, 
and substance addiction. (Table 1). A meta-analysis of four trials test-
ing the effects of psilocybin on symptoms of anxiety and depression 
found that, although sample sizes were small, both within-group 
and placebo-controlled effect sizes were large (Hedges’ g=1.16-1.47 
and 0.82-0.83 respectively).91 The paradigm of therapy need not be 
restricted to these disorders: a wide variety of mental health disor-
ders may theoretically be amenable to treatment with psilocybin, 
including post-traumatic stress disorder (PTSD), anorexia nervosa, 
and functional neurological disorders.92 93 94 
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*Table adapted from Carhart-Harris and Goodwin (2017)103
Interest in psilocybin research is growing rapidly across the world, 
with completed and ongoing studies undertaken by leading academic 
and research institutes in the US, Europe and Australia.104 105 106 107 108 
109 110 111 112 113  In 2018, the US Food and Drug Administration granted 
‘breakthrough therapy’ status to Compass Pathways Ltd – a British 
venture capital funded life sciences company – for psilocybin ther-
apy in treatment resistant depression.114 The following year, the FDA 
awarded the same status to the Usona Institute’s psilocybin program 
for major depressive disorder.115 Breakthrough therapy status is only 
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given to treatments that show early and substantial promise of a sig-
nificant treatment advance in the field. Johns Hopkins University has 
recently announced the launch of its $17M donor-funded Centre for 
Psychedelic and Consciousness Research, which is currently study-
ing the potential of psilocybin as a treatment in anorexia nervosa and 
in depression – including in patients with Alzheimer’s Disease, for 
which there is currently no effective therapy to improve quality of life 
for patients and their carers.116 117  
Significant advances in the field are being accomplished by 
UK-based institutes and funders. King’s College London recently 
launched ‘The Psychedelics Trials Group,’ led by Dr James Rucker, 
funded by a £1.2M grant from the National Institute for Health 
Research (NIHR) and contributions from industry (£600K annually). 
Aided by a £3 million grant from a number of entrepreneurial donors 
and charitable trusts, Imperial College London recently launched the 
‘Centre for Psychedelic Research.’118 Imperial’s Psychedelic Research 
Group was the world’s first to investigate the effect of LSD on the 
human brain using modern brain imaging and to study psilocybin for 
the treatment of resistant depression. 
Compass are now the first company in the world to manufacture psil-
ocybin to the pharmaceutical quality required for a medicine – a nota-
ble achievement in the face of Schedule 1 restrictions. It is the spon-
sor of a late phase 2 trial of psilocybin in treatment resistant depres-
sion and recently completed the largest ever randomised study of 
psilocybin, in collaboration with Dr James Rucker and Professor 
Allan Young at King’s College London.119 120 89 healthy volunteers 
received psilocybin in a randomised, controlled trial that explored 
changes in cognitive and emotional processing before and after sin-
gle doses of psilocybin and placebo. The study found that psilocybin 
caused no statistically significant worsening of cognitive and emo-
tional measures, no serious adverse events and no adverse events that 
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led to withdrawal from the study. This is the strongest evidence yet 
for the basic safety profile of psilocybin, and the best evidence yet to 
justify ongoing, large scale research in patient populations.  
THE IMPORTANCE OF PSILOCYBIN 
RESEARCH 
Psilocybin therapy may be a novel and paradigm-shifting develop-
ment in the treatment of mental health conditions. It works in a dif-
ferent way to traditional antidepressants and psychological therapies, 
by directly decreasing activity and changing patterns of connectiv-
ity in brain regions strongly associated with ongoing depression and 
anxiety.121  This enables patients to challenge overly rigid, negative 
thought patterns and behaviours that often underlie psychiatric dis-
orders like depression, particularly in treatment resistant cases.122 
123 124  Patient accounts of psilocybin therapy indicate two major psy-
chological themes underpinning therapeutic change: (1) a move-
ment from a sense of disconnection to connection - to self, others and 
the world; and (2) a movement from emotional avoidance to accept-
ance.125 Clinical trial evidence suggests that psilocybin may be effec-
tive in groups where traditional treatments have failed (Table 1). This 
is where the clinical and health-economic problem lies, where new 
treatments are most needed, and where commercial potential exists.
Psilocybin therapy is likely to be cost-effective for health service 
providers, relative to existing therapies for patients with treatment 
resistant depression – such as electroconvulsive therapy (ECT), 
esketamine, and intensive talk therapy. Existing treatments have 
high costs related to the needs for dedicated personnel and treat-
ment centres and for weekly or more than weekly repeat treatments. 
Psilocybin therapy, on the other hand, has a much longer duration 
of post-treatment efficacy.126 127 128 129 130  In the most recent clinical 
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trial in treatment resistant depression in the UK, no patient required 
antidepressant treatment in the five weeks after treatment with psil-
ocybin.131 Significant effects on mood and function continued to be 
observed at 6 month follow up and some patients, with previously 
refractory illness, continue to be well 4 years later. Clinically, this 
is an intriguing and most unusual finding, underlining the poten-
tial health and socioeconomic utility, and commercial potential, of 
psilocybin.
Psilocybin therapy is practical. It is given to patients as a day case in a 
specialist day-hospital setting – in a similar manner to receiving out-
patient dialysis or chemotherapy for cancer – in a carefully controlled 
environment designed to ensure safety and comfort.132 Patients are 
supported by a therapist and psychiatrist throughout their treatment 
session to provide psychoeducation and psychological support, with 
medical care readily available if needed.133  
Psilocybin therapy is acceptable to patients. Since it does not need 
to be taken regularly to produce clinical improvements, there are 
no direct side effect burdens or risk of relapse if patients forget to 
take their medication. This model of care has inherent benefits and 
is more acceptable to patients who reject forms of treatment that 
require daily medication and may result in dangerous side effects if 
not taken as prescribed. 
Psilocybin therapy is empowering for patients. The drug acts as a 
form of psychological catalyst, helping patients work with their thera-
pist to understand why they are suffering and how their own patterns 
of thinking and behaviour perpetuate this.134 Patients who took part 
in the Imperial College open-label study reported that traditional 
medications and some short-term talking therapies tended to rein-
force their sense of disconnection and avoidance, whereas treatment 
with psilocybin encouraged connection and acceptance. They iden-
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tified themes of increased self-reflection, capacity for change, and 
motivation.135 Psilocybin can induce deeply meaningful, personally 
transformative experiences that research participants rate as among 
the most significant in their entire lives.136 These profound experi-
ences ‘sow a seed’ that the patient can take away with them, enabling 
long-term therapeutic benefit.
Finally, psilocybin therapy has a low risk of harm and diversion. It is 
delivered in specialist hospital centres and the drug is not prescribed 
for the patient to take home.137 Psilocybin is not known to cause addic-
tion, dependence or overdose at typical doses and early phase studies 
indicate a low probability of serious adverse events when delivered in 
a controlled setting.138 139 140 141 
HARMS ASSOCIATED WITH THE USE AND 
MISUSE OF PSILOCYBIN
No drug is free of harms. Nonetheless, the safety profile of psilocybin 
compares favourably to other medicinal drugs, particularly to drugs 
in Schedule 2. Experimental and clinical data on the harms of psilo-
cybin are broadly consistent with epidemiological data on the illicit 
use of psilocybin mushrooms. Users and experts consistently rate 
psilocybin mushrooms as having the lowest harms to society, public 
health and the individual of all recreational drugs, and as showing the 
most potential for benefit.142 143 144 145 146 147 148 149 150 Psilocybin induces 
acute changes to perception, mood and thought – these effects have 
a potential for harm in non-medical use but are intrinsic to the thera-
peutic value of the drug in clinical settings.151 152 153 Acute and chronic 
physiological toxicity is low and there is no evidence that psilocybin 
can cause dependence or withdrawals.154 No serious adverse events 
have been reported in contemporary clinical trials with psilocybin to 
date. There is consistent evidence that psilocybin can cause transient 
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but potentially harmful experiences of overwhelming distress. These 
experiences typically resolve within hours and are both less frequent 
and less severe in research settings than in recreational use.155 The 
social and wider criminal harms associated with the use of psilocybin 
are low.
Potential for addiction, dependence and 
abuse.
A 2018 academic review provides a thorough overview of the abuse 
potential of medical psilocybin, identifying low abuse and no physi-
cal dependence potential.156 Psilocybin is neither habit-forming nor 
classically rewarding. Animal models of abuse potential suggest weak 
reinforcing effects of psilocybin, consistent with community level 
observations of non-medical use of psilocybin-containing mush-
rooms in humans, which suggest that the vast majority of individuals 
use psilocybin only a few times and do not develop compulsive pat-
terns of use. Contemporary clinical trials with psilocybin that have 
included measures related to abuse potential showed acute elevations 
in fear and anxiety in some patients, as well as a subsequent sense of 
contentment, neither of which are predictive of a high potential for 
abuse. There is strong evidence of acute tolerance to the effects of 
psilocybin - decreased response with repeated administration - as 
well as cross-tolerance between psilocybin and other psychedelics. 
However, there is no evidence that repeated administration leads 
to physical dependence, nor to withdrawal symptoms on cessation. 
These conclusions are consistent with other reviews on the abuse 
potential of psilocybin.157 158 159 
Physiological toxicity and overdose.
The acute lethal toxicity of psilocybin is extraordinarily low. The 
lethal dose has been estimated at 1,000 times the dose commonly 
used for non-medicinal purposes; by comparison, the lethal doses 
of the Schedule 2 drugs heroin, methamphetamine, cocaine and 
THE ADAM SMITH INSTITUTE 35
codeine are approximately 6, 10, 15 and 20 times the non-medic-
inal doses respectively.160 This low potential for overdose toxic-
ity is reflected in official figures. The Office for National Statistics 
recorded only a single death associated with psilocybin use in the 
20-year period from 1993-2014.161 Whilst this may be an under-ascer-
tainment, even highly granular registries of drug deaths that collate 
coroners’ reports, toxicology analyses and medical histories have 
only recorded a handful of deaths in the UK in which psilocybin was 
implicated in the last 20 years, and fewer still where a causative chain 
of events between psilocybin and death was clear.162 A 2010 review 
of the relative physical and social harms of alcohol, tobacco, and 17 
other commonly used drugs ranked psilocybin mushrooms as hav-
ing the lowest mean physical harm and chronic toxicity of all drugs 
reviewed, and the fifth lowest potential for acute toxicity, after can-
nabis, tobacco, anabolic steroids and khat.163 
Intoxication and impairment
A UK multicriteria decision analysis reported that the largest con-
tributing factor to the harms of psilocybin mushrooms – which, 
overall, were the lowest of all 20 drugs reviewed – was ‘drug-spe-
cific impairment of mental functioning.’164 Psilocybin induces dose-
dependent changes in mood, sensory perception, and perception 
of time, space and self. It typically increases introversion and gen-
eral inactivation; and causes impairments in alertness and cogni-
tive performance. The onset of subjective effects of psilocybin is 
approximately 20-40 minutes after administration. Peak intensity 
is reached after 60-90 minutes and lasts for a further 60-120 min-
utes before subsiding, with effects typically absent at six hours after 
administration.165 
The acute effects of psilocybin on time perception, synchronization, 
attention and working memory are likely to impair the ability to drive 
or handle machines.166 167 However, trends in US motor vehicle acci-
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dents show that psychedelic drugs, unlike virtually all other classes of 
drugs, were not associated with fatal traffic accidents between 1999 
- 2010.168 Nonetheless, the behavioural, affective, perceptual and cog-
nitive effects of psilocybin plausibly increase harms to the individual 
in uncontrolled non-medical environments. These harms are attenu-
ated in the context of clinically supervised, dose-controlled psilocy-
bin therapies, in which many of the subjective effects are intrinsic to 
the therapeutic potential of the drug.169
Acute adverse effects
Physiological side effects of psilocybin mushrooms may include 
dilation of the pupils, mild increases in heart rate and blood pres-
sure, dizziness, nausea, abdominal discomfort, shivering, and head-
aches.170 Acute psychological side effects include visual illusions, 
dream-like states, and anxiety. Non-serious side effects of psilocy-
bin are relatively common in research settings.171 Aside from head-
aches, which resolve over 24-48 hours, side effects are almost always 
resolved by the time the drug’s effect has worn off, after 6-8 hours. 
Typically, these minor side-effects are not clinically significant. 172 173 
174  
In clinical trials, a ‘serious adverse event’ is defined as an event that: 
is life-threatening; requires hospitalisation or prolongation of exist-
ing hospitalisation; results in persistent or significant disability, inca-
pacity, or death; or consists of a congenital anomaly or birth defect. 
No such events have occurred in clinical trials with psilocybin to 
date. 175 176 177 178 Psilocybin therapies are provided over a small num-
ber of sessions in a contained, safe and supervised setting. Patients 
are not given psilocybin to take home. Thus, any side effects are con-
tained and not ongoing, unlike most other standard antidepressant 
therapies.
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Acutely distressing psychological 
experiences
The use of psilocybin and other psychedelic drugs carries certain 
psychological risks in both recreational and clinical contexts – in 
particular, acute experiences of overwhelming distress known col-
loquially as ‘bad trips.’ While dysphoric experiences are rare and 
the majority do not result in dangerous or harmful behaviour, risks 
are increased in unprepared individuals or uncontrolled situations. 
A survey study on the single most psychologically difficult experi-
ence of almost 2000 individuals, after consuming psilocybin mush-
rooms in non-medical settings, identified risks to users of acute fear, 
putting themselves or others at risk for physical harm, and seeking 
medical help. Counterintuitively, 84% of respondents endorsed ben-
efiting from these experiences.179 In historical clinical and research 
settings and in uncontrolled non-medical settings, extreme panic or 
delusional reactions to psychedelic drugs have resulted, albeit rarely, 
in increased suicidality during the experience.180 181 182 183 This has not 
been reported in contemporary studies.
In research conditions, the incidence of dangerous behaviours or 
enduring psychological distress is extremely low and can be further 
minimised with participant preparation, clinical supervision and 
psychological support. Persistent and severe distress in medical set-
tings can be managed with commonly available drugs, such as benzo-
diazepines and antipsychotics, that attenuate the effects of psilocy-
bin.184 Nonetheless, distressing experiences do still carry risks, such 
as research participants leaving the study site.185 The acute effects of 
psilocybin therapy are rarely enjoyable for depressed patients, though 
most later consider such difficult experiences to be worthwhile.186 
Indeed, exposure to difficult experiences that may be driving depres-
sion is thought to be a necessary stage in the psychological process of 
change towards a more positive personal perspective, which logically 
may underpin the lasting positive outcomes seen in some patients 
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treated with psilocybin therapy.187 188 189 
Long-term mental health effects
There have been no recorded incidences of prolonged psychosis in 
contemporary clinical or experimental trials.190
In rare cases, the administration of psychedelic drugs has been 
reported to precede prolonged perceptual disturbances or episodes 
of mental illness, including psychosis, that may last from days to sev-
eral months or longer.191 192 193 194 These risks were reviewed in safety 
guidelines for psychedelic research published in 2008.195 Prolonged 
effects are uncommon and it is still unclear how onset is linked caus-
ally to drug administration. It is particularly difficult to deduce cau-
sation when there is a considerable interval between the administra-
tion of the drug and the onset of the psychological change – a 1966 
BMJ article, which highlighted potential risks of LSD, noted that 
events were separated by weeks or months in many cases of violent or 
otherwise aberrant behavior that had been linked to administration 
of the drug.196  In such cases, pre-existing personal and social risk fac-
tors for such behavior are often identified, and much more likely to be 
aetiologically salient. 
There is some evidence that psychedelics can exacerbate or pre-
cipitate symptoms in psychotic patients and individuals with a pre-
disposition to psychosis, but little to no evidence of prolonged epi-
sodes induced in otherwise low-risk individuals.197 198 Only one case 
of a lasting psychotic reaction was documented in 1,200 non-patient 
research participants who took part in studies prior to 1960, affecting 
an individual whose identical twin was diagnosed with schizophre-
nia.199 200 It is now known that the concordance rates of schizophrenia 
for identical twins is approximately 40-50%.201 The 1966 BMJ article 
hypothesized that “most of the patients who have developed these 
adverse reactions should not have been given the drug since they 
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were manifestly unstable or pre-psychotic.”202  
Enduring psychological symptoms of a non-psychotic nature have 
also been reported after difficult and distressing drug experiences, 
particularly in non-medical settings in which little or no psychologi-
cal support may be available.203 Historical and contemporary clini-
cal observations suggest that particularly challenging psilocybin 
experiences can cause continued psychological difficulties if they 
are not worked through.204 One patient in a recent open-label trial 
using psilocybin for treatment resistant depression in the UK was 
offered additional psychotherapeutic integration sessions to come to 
terms with an apparently repressed memory that surfaced during the 
treatment.205 
Cases of persistent perceptual abnormalities have been docu-
mented following the use of psilocybin and other psychedelics.206 
‘Hallucinogen persisting perception spectrum disorders’ (HPPSD) 
are a cluster of syndromes characterised by prolonged percep-
tual effects and clinical distress or impairment. The incidence is 
unknown but is thought to be extremely uncommon. Illicit drug use 
is associated with greater risks of HPPSD than administration in 
research or treatment settings.207 It is more commonly diagnosed in 
individuals with a history of previous psychological issues or sub-
stance misuse, and more commonly precipitated by LSD, PCP and 
cannabinoids than by psilocybin.208 
In a 1960 survey study of investigators who had administered the 
psychedelic drugs LSD or mescaline (which are pharmacologically 
similar to psilocybin), suicide attempts and completed suicides, 
occurring some weeks after treatment, were reported in 0.12 and 
0.04% of patients respectively. There were no reports of attempted 
or completed suicides reported for 1,200 experimental (non-patient) 
research participants.209 Nor have there been any incidents docu-
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mented in or subsequent to contemporary clinical or experimental 
studies. 
In clinical, laboratory and population-studies, the most common 
persisting effects of psilocybin seem to be beneficial.210 Open-label 
and randomised controlled clinical trials consistently report reduc-
tions in measures of depression and anxiety for several months after 
administration.211 212 213 214 215  Studies in non-patient research partici-
pants also report long-term increases in well-being, life satisfaction, 
interpersonal closeness, gratitude and life meaning.216 217 218 Large sur-
vey studies have identified robust associations between the illicit use 
of psychedelic drugs and reduced odds of psychological distress, sui-
cidal ideation, attempted suicide, opioid dependence, and antisocial 
behaviour.219 220 221 222
Social and criminal harms of misuse
Psilocybin therapies are provided under clinical supervision for the 
duration of the drug effect and are, accordingly, unlikely to increase 
social harms related to acute intoxication. Nor are social harms likely 
to be affected by the diversion of medical psilocybin to the illicit mar-
ket, since psilocybin is not prescribed for patients to take home and 
the major source of diverted medicinal drugs is by prescription prior 
to diversion.223 This view is consistent with ACMD advice that “the 
risk of diversion and misuse [of controlled drugs] in a research setting 
is likely to be minimal.”224 
Psilocybin-containing mushrooms are not popular as a recreational 
drug in the UK, and psilocybin itself is rarely, if ever, used outside of 
medical research. Government estimates of the rate of non-medici-
nal use of psilocybin mushrooms are low relative to many other con-
trolled drugs of abuse: from 2008/9 to 2018/19, the average propor-
tion of 16 to 59 year olds who reported past-year use of psilocybin-
containing mushrooms was 0.4%. In comparison, the average past-
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year use rates were 6.7% for cannabis, 2.4% for cocaine and 1.5% for 
ecstasy over the same time period.225
Over half of all UK acquisitive crime is committed to fund drug 
misuse, primarily by low income dependent users of heroin and 
cocaine, costing society an estimated £13.9 billion annually.226 227 228 
229 However, psilocybin and psilocybin-containing mushrooms do 
not cause dependence syndromes and, in 2005, the Home Office 
reported “no clear evidence of a link between psilocin use and 
acquisitive or other crime”.230 Conversely, there is some evidence 
that psilocybin may reduce the likelihood of criminal behavior. 
Survey data exploring the connections between drug use and crim-
inal behaviour among almost half a million US adults over 13 years 
found that respondents who had used psychedelic drugs, such as 
psilocybin, had 27% decreased odds of committing larceny or theft, 
22% decreased odds of past year arrest for a property crime, and 18% 
decreased odds of past year arrest for a violent crime. Lifetime use of 
other controlled drugs was associated with increased odds of crimi-
nal behaviour.231
A multicriteria decision analysis on drug harms in the UK found no 
evidence for substantial harms of psilocybin mushrooms related to 
loss of tangibles, loss of relationships, community, crime, environ-
mental damage or economic cost. The overall rating of harm was 
the lowest of all drugs and there was no reported harm to others.232 
In 2000, a risk assessment of psilocybin by the Dutch Co-ordination 
Centre for the Assessment and Monitoring of new drugs (CCAM) 
found that the risk to public order was low.233 The Dutch National 
Criminal Intelligence Service found no evidence of public nuisance 
related to the use of psilocybin mushrooms; though forensic physi-
cians in Amsterdam, where psilocybin fungi are openly sold, have 
reported low numbers of arrests for public nuisance and violation of 
traffic laws.234 
42 THE ADAM SMITH INSTITUTE
Healthcare costs of drug use are a major contributor to societal 
harms. Psilocybin mushrooms are not associated with any substan-
tial burden of healthcare costs, based on a global survey of more 
than 12 million people, which found that approximately 0.2% of peo-
ple required emergency medical attention after using psilocybin 
mushrooms recreationally – the lowest rate estimate of all reported 
drugs.235 




The legal controls on psychedelic drugs in the UK, and interna-
tionally, have been shaped by commitments made under three 
United Nations treaties on drug control, namely, the 1961 Single 
Convention on Narcotic Drugs, the 1971 Convention on Psychotropic 
Substances, and the 1988 Convention Against Illicit Narcotic Drugs 
and Psychotropic Substances.236 237 238 Shaped and influenced by the 
provisions of these treaties, the domestic laws of most countries cur-
rently enforce strict regulations with respect to the medical and sci-
entific availability of psychedelic drugs, and impose severe criminal 
penalties for their unlawful production, supply and use, notwith-
standing that such measures are, arguably, incommensurate with the 
scientific evidence as to their harms to society and to the individu-
al.239 In practice, the intensity of legal control concerning the produc-
tion, distribution and use of drugs is a matter for each contracting 
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state.  Furthermore, international treaties do not have a direct effect 
on the UK. Accordingly, the UK has room for manoeuvre under the 
Conventions, by which clinical research of psychedelic drugs might 
be facilitated by appropriate legislative action. 
INTERNATIONAL DRUG CONTROL 
TREATIES
Various international drug control agreements, dating back to at least 
the 1912 Hague Opium Convention, were terminated and super-
seded by the 1961 UN Single Convention on Narcotic Drugs.240 
Though earlier treaties established prohibitions and limited certain 
actions to medical and scientific purposes, the 1961 Convention cre-
ated a broader and more tightly controlled international approach 
and established the goal to eliminate non-medical opium use over a 
15-year period and the use of cannabis and coca over 25 years.241 
The Single Convention specifies four lists [schedules] of drug sub-
stances (with a total of more than 100 substances named) subject to 
control under the terms of the Convention, and a protocol was pro-
vided for adding new drugs without requiring amendments to the 
Convention.242 The Single Convention was the first drug control 
treaty to focus on the cultivation of drug plants, putting the burden 
on producer countries to eradicate traditional use of those plants.243 
Contracting parties were required to introduce domestic drug con-
trol laws that give effect to its provisions and, in particular, to its pri-
mary aim  to “limit exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution of, trade in, 
use and possession of drugs”.244 That aim remains the cornerstone of 
international drug policy. 
Two further UN drug conventions have been ratified by the UK. The 
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1971 Convention applies to an even wider range of drugs including 
amphetamines, barbiturates, benzodiazepines and psychedelics.245 
According to a UN staff member of the Division of Narcotic Drugs 
at the time, the 1971 Convention consisted of two treaties, one outlin-
ing the strict controls for substances in Schedule I (i.e. psychedelic 
drugs), and the other covering weaker restrictions on pharmaceuti-
cals in Schedules II, III and IV.246 The disparity was, in part, a result 
of lobbying pressure from the European and American pharmaceu-
tical industries.247 As Schedule I drugs, psychedelics are subject to 
the following controls as outlined in art.7a: “Prohibit all use except 
for scientific and very limited medical purposes by duly authorized 
persons, in medical or scientific establishments which are directly 
under the control of their Governments or specifically approved by 
them”. 248 This is more restrictive than the terms of art.4 of the Single 
Convention.
The 1988 Convention established additional legal mechanisms for 
enforcing the preceding treaties.249 A key purpose of the convention 
was to promote international cooperation between consumer and 
producer countries to suppress trafficking. Parties agreed to estab-
lish the unlicensed manufacture, distribution or transport of psyche-
delic precursors as criminal offences.250  
UK REGULATIONS ON THE USE OF 
CONTROLLED DRUGS IN SCIENCE & 
MEDICINE
The regulation of medicinal products - substances that are presented, 
used, or intended for the treatment or prevention of disease, modi-
fication of physiological function, or to make a medical diagnosis – 
has long been governed by legislation including the Therapeutic 
Substances Act 1925 (repealed and superseded by an Act of the same 
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name in 1956, which was itself repealed in 1993), the Medicines Act 
1968, the Poisons Act 1972, and the Human Medicines Regulations 
2012.251 Oversight of medicines for human use is the responsibil-
ity of the Medical and Healthcare products Regulatory Agency 
(MHRA), the product of a merger of the Medicines Control Agency 
and Medical Devices Agency in 2003.252 The MHRA performs a 
variety of functions in connection with medicinal products including 
the granting of marketing authorisations. As with its parent agencies, 
the MHRA is an executive agency of the Department of Health and 
Social Care (DHSC).253 
The regulation of controlled drugs – drugs that are dangerous or oth-
erwise harmful and liable for misuse – is laid out under the Misuse 
of Drugs Act 1971, which repealed and superseded the Drugs 
(Prevention of Misuse) Act 1964, and the Dangerous Drugs Acts of 
1965 and 1967. The 1971 Act and its associated regulations consti-
tute a mechanism by which the unauthorised supply and posses-
sion of controlled drugs is prohibited, whereas actions in respect of 
controlled drugs for medicinal or scientific use may be permitted. 
Medicinal drugs with a potential for harm may, therefore, be con-
trolled under both medicines legislation and under the 1971 Act and 
its regulations. The 1971 Act was enacted and subsequently amended 
with consideration of the UK’s treaty obligations under international 
drug conventions.254 It lists controlled drugs in three classes (A, B, C) 
and defines criminal offences relating to their cultivation, produc-
tion, supply, movement or possession. The classes are intended to be 
reflective of the relative potential harms of misuse. However, drug 
classification is a contentious issue and criticised for lacking scien-
tific validation.255 256 257 258
The 1971 Act and subsequent regulations provide various powers 
to the UK Home Office. Section 7(3) of the Act requires the Home 
Secretary to make regulations to permit the authorised medical 
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use of controlled drugs. The secondary legislation associated with 
Section 7(3), the Misuse of Drugs Regulations 2001, stipulates the 
conditions under which the professional use of controlled drugs can 
lawfully occur. The 2001 Regulations particularise controlled drugs 
into five schedules (see Box 1), and, alongside the Misuse of Drugs 
(Safe Custody) Regulations 1973, define the regulation of their sup-
ply, prescription, storage, destruction and record keeping.
Section 7(4) of the 1971 Act grants the Home Secretary power to des-
ignate certain drugs as being exempt from Section 7(3) if “it is in the 
public interest” to do so. Section 7(4) provides that, under such cir-
cumstances, the “production, supply and possession of that drug to 
be either wholly unlawful or unlawful except for purposes of research 
or other special purposes.” The Misuse of Drugs Designation Order 
2015 lists drugs to which this Section applies, and which may not be 
used lawfully except under a license or other authority issued by the 
Home Office.
Psilocin and its esters (including psilocybin) are listed in Class A of 
the 1971 Act, Schedule 1 of the 2001 Regulations and Part 1 of the 
2015 Order. Accordingly, psilocybin cannot be produced, supplied 
or prescribed without specific Home Office approval. Amendment 
of the schedule of a drug under the 2001 Regulations does not 
require primary legislation and may be achieved through the use of 
a Statutory Instrument laid by the Home Secretary under the nega-
tive procedure after consultation with the Advisory Council on the 
Misuse of Drugs. 
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Box 1: Schedules of the 2001 
Regulations
Schedule 1 includes drugs that are not available for scien-
tific or medical use without specific approval from the Home 
Office. Schedule 1 drugs include psilocybin, LSD, MDMA, 
khat, coca leaf, raw opium, and cannabis other than ‘canna-
bis-based products for medicinal use’ (CBPM).322 A con-
trolled drug register must be used to record details of any 
Schedule 1 drugs received or supplied by a pharmacy. 
Schedule 2 includes drugs that are available for prescription 
without specific Home Office approval, subject to special 
controls regarding safe custody and prescription. Schedule 2 
drugs include opiates (e.g. diamorphine (heroin), morphine, 
methadone hydrochloride), major stimulants (e.g. ampheta-
mine, methamphetamine), cocaine, ketamine and CBPM. A 
controlled drug register must be used to record details of the 
acquisition and use of Schedule 2 drugs. 
Schedule 3 includes substances subject to special prescrip-
tion regulations and safe custody regulations (with some 
exceptions). Schedule 2 requirements for record keeping and 
storage do not apply to Schedule 3 drugs, which include bar-
biturates and Flunitrazepam (also known as Rohypnol). 
Schedule 4 (Parts 1 & 2) includes drugs that are not subject 
to special prescribing arrangements nor safe custody require-
ments. Predominantly, drugs in Part 1 are benzodiazepines, 
and those in Part 2 are steroids. Drugs in Part 2 are exempt 
from the prohibitions on importation, exportation and pos-
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from the prohibitions on importation, exportation and 
possession when in the form of a medicinal product. 
Schedule 5 is reserved for preparations with low concentra-
tions of active ingredient, and therefore low strength. These 
substances are exempt from most of the requirements per-
taining to controlled drugs. 




SCHEDULE 1 REGULATIONS INCREASE 
COSTS, DURATION AND DIFFICULTY OF 
RESEARCH
The Schedule 1 status of psilocybin hinders research. This is par-
ticularly important to understand and rectify in view of the new Life 
Sciences Sector Deal. This has identified life sciences and pharma as 
a flagship UK industry post-Brexit. With the expertise that exists in 
the UK, we are well placed to lead the world in psychedelic research. 
However, Schedule 1 restrictions significantly impede this poten-
tial and reduce the economic impact of this research.  Moving drugs 
with high research value from Schedule 1 to Schedule 2 will support 
medical and pharmaceutical research, while continuing to guarantee 
secure and responsible stewardship of substances in a small number 
of properly regulated organisations.
Although small clinical trials and limited animal studies with psilo-
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cybin are being conducted in the UK, Schedule 1 regulations increase 
the costs, difficulties and duration of research. It is particularly 
important to highlight the added burden on universities, funders, 
personnel and patients in comparison with research into Schedule 2. 
Universities do not usually need a licence to possess and supply con-
trolled drugs in Schedules 2 to 5 of the Misuse of Drugs Regulations 
2001, but a controlled drugs (CD) licence is required to possess and 
supply controlled drugs listed in Schedule 1, including psilocybin. 
The issues described below do not apply to Schedule 2 drugs.
The barriers to research have been highlighted in peer-reviewed pub-
lications, including survey studies of researchers.259 260 A 2018 survey 
study of members of the British Association for Psychopharmacology 
concluded that “current UK legislation hampers research into 
the consequences, and potential therapeutic benefits of Schedule 
1 drugs”.261 Respondents to the survey described the frustration 
vividly:
“As it stands, it is so difficult to even contemplate 
research in this area as you almost have to think ‘Right, 
we might, if all goes well, be able to start in two years’” 
“In short, I can tell you without hesitation that the cur-
rent legislation surrounding controlled drugs is stifling 
research in this area: it has essentially dissuaded me 
from continuing my work. I no longer work on controlled 
drugs.”  
In comparison, working with Schedule 2 drugs was reported to be 
substantially easier: 
“We routinely use Schedule 2 drugs for experiments in 
animals. Processes for ordering and management work 
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well. Schedule 1 drugs are much more difficult due to 
additional licensing which effectively precludes using 
these compounds despite potential value for preclinical 
research.”  
Most recently, an extensive analysis of UK University researchers 
has been conducted by academics at the University of Manchester 
(including the author JN), with a focus on psilocybin. Initial analy-
sis shows significant and extensive barriers to research encountered 
by all personnel involved. This study included detailed interviews 
with a range of UK researchers, including clinicians, pharmacists, 
psychologists, imaging scientists, and animal researchers, and will be 
published in a peer reviewed scientific journal in Q4 2020. In 2020, 
the ACMD also conducted a survey of UK pharma and universities 
on Schedule 1 barriers to research with a focus on synthetic cannabi-
noids. Researchers in the US, where these drugs are also listed under 
the most restrictive schedule, face similar challenges. 262 263 264  
In summary, Schedule 1 regulations raise barriers at every stage of 
scientific inquiry from preclinical to late phase clinical research by 
adding costs, delays and stigma, thereby impacting funding, ethi-
cal approval, recruitment and collaboration. These barriers, which 
are well known among the research community and have been rec-
ognised in Parliamentary reports for at least twenty years, prevent 
many studies from taking place and substantially complicate those 
that do.265 
Costs
The costs associated with Schedule 1 regulatory requirements, 
including licensing, negatively impact research at all stages, increas-
ing the burden on large-scale clinical studies and effectively pre-
cluding many academics from conducting valuable experimental 
research.  The authors JR and JN currently undertake clinical and 
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non-clinical research with Schedule 1 drugs in the UK and can thus 
attest to the costs and burdens as of 2020.
A controlled drugs licence costs approximately £3,000 and is renew-
able every 12 months, with a renewal fee of approx. £325, or £1,370 if 
an inspection is required. Separate Schedule 1 licenses are required 
at every stage of the supply chain, from the manufacture of the active 
substance (API), to the manufacture and preparation of the finished 
product, through to dispensing and administration. Mandatory 
import and export licenses for compounds that are moved between 
research partners and sites create additional costs and administrative 
burden, and limit opportunities for researchers to work international-
ly.266 267
Schedule 1 regulations confer a particularly significant burden for 
large-scale, multi-site phase 3 clinical studies, which are already 
costly and administratively complex. These trials are essential to pro-
vide the safety and efficacy data required for regulatory approval of 
new drugs, and to guide future clinical research objectives.268 Every 
site at every clinical trial must have a separate Schedule 1 ‘adminis-
ter’ license, which names medical personnel who can prescribe and 
nursing staff who can administer the drugs. Every pharmacy that dis-
penses Schedule 1 drugs must have a separate ‘dispensing’ license 
and every pharmacy that packages or otherwise handles Schedule 1 
drugs must have a separate ‘manufacturing’ license.269 In practice, 
the process of manufacturing the drug substance, ensuring qual-
ity and purity standards are met, and then encapsulating the drug 
substance are all undertaken by different pharmacies, all of which 
must have the relevant Schedule 1 licenses that, again, are renewed 
annually. 
The burden imposed by license applications, however, pales in com-
parison to the practical and financial implications of Schedule 1. At 
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the time of writing, JR has just signed a contract with a pharmacy 
that holds a Schedule 1 manufacturing license to supply 120 doses 
of psilocybin and placebo for a clinical trial. The activity of the phar-
macy is to put capsules of psilocybin or placebo in a plastic bottle, 
label them and then send them to the hospital pharmacy. This seem-
ingly minor task is complicated by Schedule 1 regulations mandat-
ing extremely strict security standards, including specially designed 
safes, vetting of personnel and 24-hour CCTV coverage. 
This contract is valued at £42,000, or about £400 per dose of psilocy-
bin. A large proportion of this cost is directly attributable to Schedule 
1 legislation and would not be required at all if psilocybin was a 
Schedule 2 drug, since the local hospital pharmacy would be able to 
undertake this task. It is germane to note that the UK Government 
will be paying the cost of this contract, since the money for this trial 
comes from UK Government itself via the National Institute of 
Health Research. This is a waste of the taxpayers’ money and scarce 
grant funding that could be used for other research. 
It is difficult to put an exact overall figure on the financial burdens 
of Schedule 1, partly as they are indirect and nebulous. Compass 
Pathways Ltd, which manufactures psilocybin in the UK and makes 
it freely available to researchers undertaking licensed, authorised 
research, have estimated that the cost of developing, manufactur-
ing and encapsulating the first batch of psilocybin was in the region 
of £2,000,000, a significant proportion of which was due to the bur-
dens imposed by Schedule 1 regulations. A health economic analy-
sis of rescheduling is to be published by the CDPRG in a subsequent 
report, quantifying the additional costs of bringing a Schedule 1 drug 
to market.
“In our first study of psilocybin in the treatment of 
resistant depression, I calculated that because of the 
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extra costs incurred by the Schedule 1 status of psilocy-
bin, each dose cost around £1,500 – more than ten times 
the amount if the restrictions were not in place. This 
money is taken from research grants and so undermines 
their financial viability and reduces their extent. It also 
took us over 2 years to get the permissions to conduct the 
research, which represents a huge lost opportunity cost.”  
Professor David Nutt, Imperial College London 270
Delays
Long delays related to Schedule 1 regulations are reported by 
research staff to occur at multiple stages in the research process, typ-
ically related to licensing, ethical approval and other administrative 
requirements. For instance, the ongoing University of Manchester 
analysis into barriers to controlled drug research identified delays 
associated with the Schedule 1 license application process, par-
ticularly for new applicants. One pharmacist reported difficulties 
with the online application form, which requires the applicant to 
enter information that can be time-consuming to gather, but which 
does not provide a list of required documentation at the beginning. 
The form does not permit going backwards to previous sections of 
the form and ‘times out’ after a certain period, meaning that appli-
cants may have to restart the form numerous times before it can be 
completed. 
“The first screen might say you needed a list of who is 
responsible in your trust for security or governance or 
medicine, so you’d go away and try and find all this infor-
mation, but it would take you a while. Then you would 
come back, click on the next screen and it would be talk-
ing about: “What is your alarm system; What is the 
response to your alarm system; When does it need test-
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ing; Who does the testing; What’s your serial number?” 
So, you’d go away and try and find that, come back, click 
into the next screen and then it would say that somebody 
who’s head of security needs to be DBS checked and your 
normal hospital DBS checks weren’t applicable. They 
had to get a separate special DBS check for Schedule 1 
drugs, which meant somebody quite senior in your trust 
had to go down to the post office with all their ID and get 
all that officially checked by the Post Office and sent off, 
and then that meant that form that you’d filled out gets 
cancelled [because of the time delay]. So then, because 
you didn’t have the information you needed at hand you 
then had to then start the form all over again.”
Research staff reported that once Schedule 1 license applications 
have been submitted, the validation and approval process (which 
may involve inspections from compliance officers) may add further 
delays of many months, or even years, for every necessary license to 
be granted. Previous survey data on barriers to research indicates 
that, in some cases, the Home Office has requested ethical approval 
before granting an initial licence, while ethics committees have 
requested Home Office licensing before considering the application 
- an impasse that causes further frustration, excess paperwork and 
long delays.271
At all stages of research, delays are caused by the additional back-
ground work that administrators and researchers must conduct to 
understand Schedule 1 regulatory requirements. Applicants may 
not be familiar with the licensing process, since universities do not 
require specific controlled drug licenses for research with other con-
trolled drugs such as heroin, cocaine, and methamphetamine, all of 
which are in Schedule 2. According to the University of Manchester 
analysis, many research staff feel that there is limited available help 
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provided to applicants by regulators and that the rules and require-
ments can be challenging to understand. Indeed, current regulations 
regarding the use and storage of small quantities of Schedule 1 drugs 
for research have been described by the ACMD as ‘problematic’ 
and unclear.272 Compound libraries are used by both industry and 
academia, containing small amounts of substances stored in multi-
well plates in a computerized repository. It is problematic to store 
Schedule 1 drugs in such libraries, since regulations dictate that they 
must be stored in locked cabinets regardless of quantity.273 
There are a wide range of further delays associated with Schedule 
1 research, from contracting the specialist pharmacy services 
discussed previously, to the increased daily work involved with 
the added regulations on the storage, record-keeping and move-
ment of Schedule 1 drugs at research sites. These delays will be 
addressed more comprehensively in the forthcoming analysis from 
the University of Manchester. In addition to the obvious impact on 
the speed of scientific progress, all delays also translate into higher 
research costs, since research staff must be employed for greater 
periods of time. 
“We had to wait one year to obtain our [Schedule 1] con-
trolled drugs (CD) licence to investigate effects of can-
nabinoids in rats. This is an enormous delay. We can-
not move the drugs outside of our building. This means 
that a colleague working on the same project in another 
building could not work under the permission of our CD 
licence. To have one licence for each building within an 
institution is very restrictive, expensive and time-con-
suming (for us and the Home Office) and does not enable 
academic collaboration which is essential for the success 
of research.”
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Professor Joanna Neill, University of Manchester274
Stigma
Stigma is a huge issue with researching drugs in Schedule 1, even in 
animals. The stigma of Schedule 1 status perpetuates cultural biases 
against this category of controlled drugs and increases the difficulty 
of academic collaborations, obtaining ethics approval, and achiev-
ing institutional funding through research.275  The impacts of stigma 
were recognised as early as 1998 in a Science and Technology Select 
Committee Report, which reported:
“Transfer [of cannabis] to Schedule 2 would also go 
some way to removing the stigma which many of our wit-
nesses believe hangs over research in this field, deter-
ring researchers, funding bodies, pharmaceutical com-
panies and local ethics committees alike from involve-
ment in research which might turn out to be of great 
importance.”
Science and Technology Select Committee (1998)- Ninth 
Report: Cannabis276
The University of Manchester analysis has also identified negative 
impacts of stigma in both clinical and non-clinical research with psil-
ocybin, clearly indicating that this issue has not been resolved in the 
past two decades:
“There are several different people in a range of depart-
ments who all have to agree in order for Schedule 1 
research to happen. Many of them have anxiety about 
engaging in research with a Schedule 1 drug because they 
are considered to be “high risk”. This starts a bureau-
cratic process of oversight and audit, which does not hap-
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pen for research with other drugs that are considered 
low-risk. Schedule 1 research is considered high-risk, 
politically sensitive, and that creates a lot more bureau-
cracy; different departments around the university that 
may not otherwise want to know about what is going on, 
suddenly want to know about the research.”
Clinical trial example, University of Manchester analysis
“For preclinical research, each study is approved by a 
range of staff at the animal facility- (in addition to hav-
ing a project licence from the Home Office for the pro-
gramme of work, Animals Scientific Procedures Act 
1986). To use psilocybin in animals we had to have extra 
precautions because it is a Schedule 1 drug. This included 
a meeting with the animal facility team, a report made 
to the Home Office and after the 1st safety study, an 
amendment to the project licence which can take up to 
6 months. We have never had to do this for a schedule 
2 drug. This is a good example of the stigma associated 
with schedule 1 research and the negative impact that has 
on the research.”
Animal study example, University of Manchester analy-
sis 277
SCHEDULE 2 REGULATIONS SUPPORT 
LEGITIMATE RESEARCH WHILE 
MAINTAINING SAFEGUARDS
Researchers and other stakeholders, including the Home Office, have 
consistently reported that research is more easily conducted under 
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Schedule 2 regulations than under Schedule 1. The University of 
Manchester analysis on barriers to research identified a widespread 
belief among research staff that rescheduling psilocybin would facili-
tate scientific development while retaining the controls necessary to 
prevent unintended harms:
“A lot of the regulations and practical security require-
ments surrounding the custody, transport & adminis-
tration of the drug would be removed [if psilocybin were 
moved to Schedule 2]. Not all of them, because Schedule 
2 drugs still have strict safe custody, security and admin-
istration requirements. But it would mean that we 
wouldn’t need any of those Schedule 1 licences because 
you would have a specific exemption to do the research. 
In summary, re-scheduling would make the research eas-
ier whilst still maintaining the security and safe custody 
processes that are necessary.”  
Representative excerpt from a clinician, University of 
Manchester analysis.
“Research sites would be able to open up a lot quicker 
[if psilocybin were moved to Schedule 2]. There would 
be more sites willing to take on people who didn’t have 
a high pharmacy presence. Mental health trusts don’t 
often have a dedicated clinical trials pharmacist or access 
to a trials pharmacist.
The licensing application itself is exceptionally time-
consuming. I can understand why they need some of that 
information but if they sent you a pack just saying we 
need to know the basics of your security and your SOPs in 
advance then we will issue the license instead of this big 
THE ADAM SMITH INSTITUTE 61
long process that we have to go through.”
Representative excerpt from a pharmacist, University of 
Manchester analysis.
“My absolute view is that there should be no difference 
between Schedule 1 and Schedule 2. I don’t think that 
there’s a particular advantage to the process of Schedule 
1 over Schedule 2. I would say that, if anything, the pro-
cess for a Schedule 2 drug works fine, you can live with 
that level of management, the process off signing off all 
the paperwork [is not difficult], but Schedule 1 is point-
less, it’s bureaucratic and hinders good science.
It would be the speed in which science could react to 
things, e.g. many years ago, we had funding for a pro-
ject in which we would have really liked to have looked at 
psychedelics. If it hadn’t been for the restrictions, I could 
have tested psilocybin in a rodent model of depression, 
five to six years ago, which would potentially be really 
useful data to have to inform what is now happening. Not 
necessarily just the clinical trials, but the fact that you’ve 
got people microdosing and self-medicating with these 
compounds, and we don’t know that data yet because it 
hasn’t been done. I could have done that work five or six 
years ago if psychedelics were not in Schedule 1. Actually, 
the drugs that I routinely use that are probably the most 
dangerous are in Schedule 2, e.g. ketamine - people use 
it as anaesthetic, not just as a research tool. I personally 
think the risks are much greater with a compound like 
that than with psilocybin.”
Representative excerpt from an animal researcher, 
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University of Manchester analysis.
Similar views were identified in the 2018 survey of members of the 
British Association for Psychopharmacology. This publication also 
reported concerns among the research community that the distinc-
tion between drugs in Schedule 1 and Schedule 2 was not based on 
scientific evidence on relative risks and harms:
“The difference in regulations for using Schedule 2 
drugs (e.g. PCP) and Schedule 1 drugs (e.g. cannabi-
noids), and difficulty in using Schedule 1 drugs is not evi-
dence-based or scientific. The current UK drug laws are 
clearly hindering research at all levels.”
A scheduling review is undertaken as part of the normal process 
when a medicinal product achieves market authorisation in the UK. 
In November 2018, however, a precedent was set for moving con-
trolled drugs (CBPM) from Schedule 1 to Schedule 2 prior to mar-
ket authorisation as a medicine. It was widely recognised that this 
change would result in improvements to the development of scien-
tific research, thereby leading to various secondary benefits to public 
health and the UK economy. At the time, the Home Office wrote: 
“The rescheduling may lead to increased UK research 
[...] as these products can be tested more easily.” “This 
may lead to economic benefits for UK businesses and 
health benefits to patients if this research leads to new 
and improved [medicinal products].” “In principle, 
research is ongoing and could lead to more effective 
treatment, lower costs, better understanding and man-
agement of risks, and improved health and wellbeing, 
over the medium term.”278 
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The current Chief Medical Adviser to the UK Government, Prof 
Chris Whitty, later stated that:
“[There] were four barriers to people getting canna-
bis products before the change in the law. The first and 
most important one at that stage was that all of those 
drugs were in Schedule 1, which made it difficult to build 
an evidence base, because, although it is possible to do 
trials under those conditions, it is extremely difficult. 
Removing that barrier is the single most important thing 
that could be done by Government at this stage. That has 
now happened, and it is a lot easier to do stuff on a sched-
ule 2 basis. The next stage is to do the trials.”279
In their written advice to the Home Office regarding the scheduling 
of CBPM, the ACMD wrote: 
“The research community has expressed concern that 
Schedule 1 acts as a ‘barrier to research’. This is impor-
tant to understand and is an issue with implications not 
just for Cannabis, but also for other Schedule 1 drugs 
where a potential therapeutic benefit has been pro-
posed… The ACMD considers that it is important that 
Cannabis is not seen in isolation but as an example of a 
wider issue of potential ‘barriers to research’ associated 
with other drugs in Schedule 1.”280
Evidently, there is widespread recognition across political and aca-
demic sectors that substantial challenges to conducting research are 
associated with Schedule 1, and that these challenges can be attenu-
ated by moving a drug with high research value to Schedule 2.  
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JUSTIFICATIONS FOR RESCHEDULING 
PSILOCYBIN
We recommend that the Home Office urgently consult the ACMD 
with a view to rescheduling psilocybin to Schedule 2, with the option 
to impose special statutory limits on access to prevent prescribing 
outside of ethically approved research studies, unless a product has 
market authorisation as a medicine. A blueprint of how this could be 
achieved is provided in the subsequent section. Under this model, 
regulatory controls on legitimate research could be lessened with-
out permitting the wider prescription of psilocybin as an unlicensed 
medicine. The scheduling of particular formulations that are brought 
to market would be reviewed in the normal way as part of the market 
authorisation process. The following section presents an overview of 
the arguments to support this recommendation.
1. There is an urgent need to support novel therapies 
in treatment-resistant mental health conditions, which 
constitute a vast social and economic burden in the UK. 
There is substantial commercial and scientific interest 
in researching psilocybin as a therapy, but Schedule 1 
regulations obstruct research. 
Schedule 1 controls substantially increase the cost, duration and dif-
ficulty of research at all stages of drug development, particularly in 
late-phase trials, which are already tightly regulated and expensive. 
Investment in new treatments for mental health has been signifi-
cantly scaled back across the pharmaceutical sector, but improved 
regulatory support would expedite commercial progress in line with 
the Department of Health’s 2017 ‘Framework for mental health 
research’ and the ‘Life Sciences Industrial Strategy’ issued by Life 
Sciences Champion, Professor Sir John Bell.281 282 The need to re-
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engage the pharmaceutical industry in mental health research is par-
ticularly salient at the current time, as the UK presently has no active 
pharmaceutical laboratories doing central nervous system research 
and development outside of universities since Eli Lilly closed their 
site in Surrey in March 2020. Accordingly, there are no psychiat-
ric drug discovery laboratory jobs for PhD students, post-doctoral 
researchers, or technicians, nor industrial placements for undergrad-
uates, posing a huge problem for UK scientific training.
The commercial potential of psilocybin therapies is considerable. 
The therapy is being developed for sufferers of treatment-resistant 
depression, a group which may comprise approximately one third of 
the 300 million sufferers of depression worldwide.283 284 Psilocybin 
therapies are also being investigated in a broad range of disorders 
related to depression, such as anxiety disorders, substance misuse 
disorders, eating disorders, functional neurological disorders, and 
other mental health problems associated with maladaptive habits of 
thinking and behaving for which there are few effective treatment 
options. There is not yet strong evidence for the use of psilocybin in 
these indications, but the broad scope of research reflects a substan-
tial and growing commercial interest.
Compass Pathways, a UK company which holds a US patent cover-
ing the use of its psilocybin formulation (COMP360) in a therapy 
protocol for patients with treatment-resistant depression, is cur-
rently running a phase 2b clinical trial recruiting 216 patients across 
Europe and North America.285 Subsequently, the safety and efficacy 
of COMP360 will need to be confirmed in large-scale phase 3 trials 
to support an application to the MHRA for market authorization. 
The normal process for market authorization will lead to a schedul-
ing review for that specific formulation – however, significant savings 
could be made by moving psilocybin to Schedule 2 early, prior to the 
commencement of phase 3 trials.
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In addition to supporting industry, rescheduling would save taxpay-
er’s money by reducing wasted expenditure of Government research 
grants (such as the £1.2 million NIHR grant supporting psilocybin 
research at King’s College London). Ultimately, reduced burdens on 
drug development would benefit public health through earlier com-
pletion of trials and lower end-costs of treatment, thereby widening 
access.
Schedule 1 controls on psilocybin also impede important non-clinical 
and preclinical research advancing scientific understanding in a wide 
range of biological systems, including the brain, the immune sys-
tem and the endocrine system.286 287 288 289 The UK is currently keep-
ing pace with other leading countries in both clinical and non-clinical 
psilocybin research, but improved regulatory support will ensure the 
UK’s reputation as a global centre of excellence in this area, attract-
ing further commercial investment and highly-skilled workers, while 
preventing a ‘brain-drain’ of British research and innovation to other 
jurisdictions that may inevitably take place when other countries pro-
vide more favourable regulatory conditions. 
Rescheduling psilocybin would be the most significant and 
immediate way that Government could support scientific and 
commercial development in this area.
2. There is no work currently commissioned by the Home 
Office that addresses the urgent issues identified in this 
report.
The ACMD are currently undertaking two relevant reviews: (1) to 
establish a Standard Operating Procedure (SOP) for scheduling deci-
sions; and (2) to understand the barriers to research with controlled 
drugs. This work is vital, and we welcome it. However, it is currently 
unclear whether the SOP will be used to review historical scheduling 
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decisions, and the initial focus of the review on barriers to research is 
intended to cover synthetic cannabinoids. Neither report is expected 
to be published until 2021, nor to directly provide recommendations 
on psilocybin. Accordingly, it is not likely that either working group 
will address the urgent and specific issues identified in this report, 
nor lead directly to legislative change prior to the commencement of 
phase 3 trials in psilocybin. See Justification (1) for more details. 
Immediate action is required to provide regulatory support to the 
development of psilocybin as a much-needed medicinal product. 
3. There is conclusive evidence that the actual harms of 
psilocybin are substantially less than the assumed harms 
underpinning original scheduling decisions in the 1970s. 
Almost half a century on from the Misuse of Drugs Act 1971 and the 
Misuse of Drugs Regulations 1973, there is little available informa-
tion on the procedural basis of classification and scheduling deci-
sions. According to the then Home Secretary, the 1971 Act was 
“drawn up on the basis of the lists of drugs controlled by the 1965 and 
1964 Acts […] in the order in which we think they should be classified 
of harmfulness and danger.”290 
Psilocybin was never listed under the 1965 or 1967 Dangerous Drugs 
Acts. In 1965, it had been added to the 4th Schedule of the Pharmacy 
and Poisons Act 1933, and, in 1966, to the Schedule of the Drugs 
(Prevention of Misuse) Act 1964. Under the 1933 Act, it could only be 
sold under prescription, and under the 1964 Act, it could not lawfully 
be possessed except by certain exempted medical and scientific pro-
fessions, nor could it be imported by any person except under Home 
Office license.291 Hansard records show that the decision to move 
psilocybin under the Schedule of the 1964 Act reflected concerns of 
severe harms posed to society and the individual by the use of psy-
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chedelic drugs, strongly influenced by accounts of LSD in the British 
media at the time.292 293 Little was known about psilocybin itself, 
which was mentioned only in association with LSD. Under the con-
trols of the 1933 and 1964 Acts, psilocybin could be freely used with-
out a license for medical and research purposes – it was not until the 
1973 Regulations that specific Home Office authorization would be 
required. It is unclear why it was then placed under more restrictive 
controls than other Class A drugs with medicinal uses, such as heroin 
and cocaine.
With the benefit of several decades of epidemiological, experimen-
tal and clinical data, which were not available to the Government at 
the time of writing the 1971 Act and 1973 Regulations, the contempo-
rary scientific consensus is that psilocybin does not pose a substantial 
risk to public health in the context of its scientific and medical use 
– or even as a drug of abuse.294 295 296 297 298 299 300 301 302 303 Early reports of 
suicide, violence and madness associated with psychedelic drugs in 
1960s media were influential in policy decisions regarding their con-
trol, but population-level studies have since found decreased odds of 
suicidality, violent crime and psychological distress linked with their 
use.304 305 306 A 2016 pharmacological review echoes this perspec-
tive: “For decades, the media have largely portrayed psychedelics as 
extremely dangerous drugs; in fact, the classic serotoninergic psych-
edelics are generally considered very physiologically safe, certainly 
compared with opiates and psychostimulants.”307
In 2005, Professor Sir Colin Blakemore, former Chief Executive of 
the Medical Research Council, told the House of Commons Science 
and Technology Committee: 
“The placing of [psilocybin and other psychedelics] in 
category A [of the Misuse of Drugs Act] was a reaction 
to the concerns about drugs which were newly available 
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on the street in the 1960s and 1970s with not much scien-
tific evidence about their actions and certainly their long 
term consequences... The evidence of toxicity is very low. 
They are not addictive and I would rate them very low in 
their potential for harm... I would say they are in a classi-
fication that if one could look at all the evidence for harm 
available now, including social harms, one would say it is 
wrong.” 
“I am sure [the Government] were using the evidence 
that was available to them at the time. The question is 
whether that evidence was fully formulated and was 
quantitatively organised in a way that would inform the 
decision well.”
The Committee quoted Professor Sir Michael Rawlins, then-Chair 
of the ACMD as saying: “I have no idea what was going through the 
minds of the group who put [psilocybin] in Class A in 1970 and 1971 
[…] It is there because it is there.”308 
We make no recommendations on the classification of psilocybin 
under the Misuse of Drugs Act 1971, but we observe that its cur-
rent inclusion in Schedule 1 of the 2001 Regulations follows an 
outdated assumption of harmfulness, implicit in its Class A sta-
tus, which is not supported by the current evidence base.
4. There is a precedent for rescheduling Schedule 1 drugs 
prior to market authorization. 
In 2018, CBPM were moved from Schedule 1 to Schedule 2 of the 
2001 Regulations, with special statutory limits placed on supply and 
use. This allowed CBPM to be prescribed as unlicensed medicines to 
patients with a special clinical need, reduced the barriers to research, 
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and established additional checks and balances to prevent diversion 
and inappropriate prescribing. We propose special statutory limits 
that could be placed on psilocybin in a rescheduling instrument that 
would impose greater controls on prescribing than are currently in 
place for CBPM. 
CBPM affected by the rescheduling are not licensed as medicines for 
any indication, in any patient group, either in the UK or internation-
ally; with the exception of Epidyolex, which has since received been 
licensed for use in the UK. At present, there is no robust evidence of 
the safety and efficacy of any unlicensed CBPM from randomized-
controlled trials (RCT).309 Therefore, with multiple phase 2 RCT 
already completed, there is a stronger evidence base on the clinical 
use of psilocybin than on any of the currently-unlicensed CBPM for-
mulations rescheduled by the Home Office in 2018.
Rescheduling psilocybin is possible and precedented. 
5. A research-only rescheduling model for psilocybin will 
limit diversion and inappropriate prescribing, and act 
as a pilot intervention to guide the resolution of wider 
barriers to research. 
Although there is a precedent for the rescheduling of Schedule 
1 drugs prior to market authorisation, there is no precedent for the 
rescheduling of a drug for research purposes only. We propose that 
piloting this approach with psilocybin may serve to inform the res-
olution of wider issues affecting research on Schedule 1 drugs. 
Statutory research-only limits may reduce the well-recognised bar-
riers to research without: (1) creating an unworkable administrative 
burden; (2) compromising the Home Office’s commitments to report 
to the INCB; or (3) increasing the risks of diversion and inappropri-
ate prescribing. An evaluation should be undertaken after 24 months 
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to assess the effectiveness of the model, with a view to applying it to 
other drugs in Schedule 1 for which there is substantial clinical, sci-
entific or commercial interest, including MDMA, LSD, DMT, fenta-
nyls, and synthetic cannabinoids. Urgent action in regard to psilocy-
bin, specifically, is justified by the registration of a psilocybin formu-
lation as an investigational medicinal product, currently being inves-
tigated in late phase trials as a therapy for treatment-resistant depres-
sion, a condition with no effective treatments – by definition – which 
affects an estimated 1.2 million people in the UK at significant social 
and economic cost. 
The ACMD working group on barriers to research with con-
trolled drugs is collecting evidence to inform an evaluation pro-
cess that has already been underway for several years. In July 2017, 
the Home Office commissioned the ACMD to review what could be 
done to facilitate research involving Schedule 1 controlled drugs. In 
December 2017, the ACMD proposed the creation of a temporary 
‘research schedule’ with reduced regulatory requirements.310 Their 
recommendation was that Schedule 1 drugs proceeding into clinical 
trials could be moved to this novel schedule, provided that the drug 
sponsor issues a detailed investigator’s brochure and ethical commit-
tee approval to the Home Office, showing evidence of safety and tol-
erability.  Under this model, drugs that are not successfully brought 
to market would revert to Schedule 1 status.
However, in January 2019, a Home Office Minister of State, Nick 
Hurd, wrote to the Chair of the ACMD to reject the notion of a novel 
research schedule on the basis of a “heavy burden on legislative 
amendment time,” since Ministers would be required to consult with 
the ACMD every time a drug was moved into or out of the proposed 
schedule.311 He commented that there “may be some further legis-
lative and non-legislative options which could be considered in fur-
ther detail.” We propose that the administrative burden identified by 
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Mr Hurd would be substantially less under research-only reschedul-
ing model proposed in this paper, since, if it is effective in addressing 
the issues in regard to psilocybin, it can later be applied to multiple 
Schedule 1 substances in a single instrument without requiring sub-
sequent consultations with the ACMD.
In their letter to the Home Office in December 2017, the ACMD also 
proposed a ‘self-policing’ approach whereby a research body would 
apply for a compound-specific exemption without disclosing the 
chemical structure, but using a unique identifier.312 This proposal 
was unlikely to apply to psilocybin, but rather to compounds cov-
ered in the 2001 Regulations by generic chemical structures com-
mon to closely related drugs. The Home Office rejected this proposal 
on the basis that it would not be compatible with the obligations of 
the UK Government to report to the INCB, on a quarterly basis, on 
materials listed in Schedule I of the UN Conventions.313 The pro-
posed research-only rescheduling model would not compromise the 
Government’s obligations in this regard, since Schedule 2 record 
keeping controls will be sufficient to inform the Government on the 
movement of drugs, as is currently the case with heroin, cocaine and 
amphetamines.
Academic reviews have found no instances of diversion of Schedule 
1 or Schedule 2 drugs from research labs, consistent with ACMD 
advice that “the risk of diversion and misuse [of controlled drugs] in 
a research setting is likely to be minimal.”314 315 In their comprehen-
sive 2016 review of the diversion of controlled drugs from the medi-
cal sector to the illicit market, the ACMD concluded that the major 
source of diverted medicinal drugs is by prescription prior to diver-
sion.316 Since psilocybin is not prescribed to patients to take home, 
diversion by this route will effectively be prevented.
Rescheduling psilocybin on a research-only basis will provide 
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immediate benefits to scientific research and commercial drug 
development, while acting as a pilot to inform the ongoing eval-
uation of barriers to research with controlled drugs, without 
increasing the risks of inappropriate prescribing or diversion.
6. Rescheduling will not affect existing controls on 
the criminal use or supply of psilocybin or psilocybin-
containing mushrooms.
Psilocybin can be moved from Schedule 1 to Schedule 2 of the 2001 
Regulations and from Part 1 to Part 2 of the 2015 Order without 
requiring changes to its classification under the 1971 Act. Multiple 
high-profile reviews have found no convincing evidence that criminal 
penalties have any substantial ‘deterrent effect’ on drug offences, but 
in the presumption that such an effect may exist, rescheduling is not 
likely to reduce it, since criminal penalties for offences will be unal-
tered.317 318 319
PATHWAYS TO RESCHEDULING
Schedules of the UN Drug Conventions
Paragraphs 5-7 of Article 2 to the 1971 Convention outline a pro-
cess for the rescheduling of a drug from one schedule of the treaty 
to another, whereby, in the light of new findings concerning a 
drug, the World Health Organization  Expert Committee on Drug 
Dependence shall communicate its findings to the United Nations 
Commission on Narcotic Drugs (CND).320 The CND may subse-
quently elect to transfer the substance between schedules, or delete 
it from them, requiring a 2/3 majority of their members according to 
Article 17.  Any such decision made by the CND must be communi-
cated by the Secretary General to all member States, to non-member 
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State parties to the 1971 Convention, the WHO and the INCB. The 
decision will come into effect for each party to the Convention 180 
days following this communication. There are precedents of such a 
process being successfully applied, such as the movement of dronabi-
nol from Schedule I of the 1971 Convention to Schedule II in 1991.321 
Achieving rescheduling of psilocybin under amendments to the 
1971 Convention through the process outlined above would support 
greater flexibility for signatory countries to adopt alternative legal 
controls on its production, supply and use. However, since interna-
tional treaties do not have a direct effect on the UK, rescheduling at 
the UN level is not necessary for the UK to move the drug between 
schedules of the 2001 Regulations. 
Schedules of the 2001 Regulations
The rescheduling of any drug listed in the 2001 Regulations requires 
amendments to that legislation by way of a Statutory Instrument 
laid by the Secretary of State under negative parliamentary proce-
dure.  The 1971 Act requires the Secretary of State to consult with 
the Advisory Council on the Misuse of Drugs (ACMD), a statutory 
advisory non-departmental public body established under the provi-
sions of the Act, though it does not oblige the Government to follow 
ACMD advice. Under such a process, psilocybin may be rescheduled 
to a more appropriate schedule commensurate with its safety profile 
and clinical potential.
Special statutory limits can be provided in the instrument, as can 
be seen in Regulation 16A of the 2001 Regulations, which imposes 
special restrictions on the order and supply of CBPM. We note that 
Regulation 16A does not make allowances for the use of CBPM in 
non-clinical or preclinical research – a limitation that we strongly rec-
ommend against. However, we do propose that the Home Office con-
sider statutory limits to prevent the order and supply of psilocybin 
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as an unlicensed medicine, as part of special checks and balances to 
avoid inappropriate prescribing and diversion. As an example, these 
restrictions could be worded in line with the following:
1) A person shall not order or supply (whether by issuing a 
prescription or otherwise) a product containing psilocin or 
esters of psilocin, unless that product is—
(a) a product without a marketing authorisation that is 
for use in a research study that has been approved by a 
research ethics committee;
(b) an investigational medicinal product without a 
marketing authorisation that is for use in a clinical 
trial; or
(c) a medicinal product with a marketing 
authorisation.
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CONCLUSION 
Schedule 1 regulations restrict the production, supply and use of 
harmful drugs to legitimate scientific and medical purposes under 
specific Home Office licenses or other authority granted by the 
Home Secretary. In practice, the regulations are a barrier to legiti-
mate research and commercial drug development, leading directly to 
delays, additional costs and increased stigma. Clinical and epidemio-
logical research has shown psilocybin to be a relatively safe drug and 
early phase trials indicate potential value as a therapy for treatment 
resistant mental health problems, including conditions associated 
with thousands of suicides annually in the UK. 
Pharmaceutical investment in new therapies for mental health condi-
tions has dried up and the UK Government has recognized the need 
to support and expedite research in this area. Psilocybin therapies are 
among the very few recent advances in mental health drug develop-
ment with substantial commercial potential, but Schedule 1 controls 
obstruct research. The single most important thing that could be 
done by Government is the rescheduling of psilocybin under the 2001 
Regulations. 
Controlled drugs may be rescheduled by a Statutory Instrument 
implemented by the Home Secretary, on the advice of the ACMD, 
without affecting existing legal controls on non-medical or scientific 
use, and there is a precedent for rescheduling controlled drugs before 
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market authorization. The risks of diversion are low and Government 
have the option to introduce statutory limits to prevent inappropriate 
prescribing. 
Swift policy change would immediately reduce the obstacles to sci-
entific research and commercial development, shortening the time 
required to bring new drugs to market and reducing the end cost of 
therapies. Under a less restrictive regulatory framework, the UK 
would rapidly become the global centre of research in this area, 
attracting international investment and expertise. Immediate action 
will yield the greatest benefits to the UK.
We urge the Home Secretary to commission a high-priority ACMD 
review into the access-restricted rescheduling of psilocybin under 
the 2001 Regulations and act swiftly on its recommendations.
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